TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Parallel Groups, Dose-finding, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of 3-wk Treatment With 1 of 3 Oral Doses of Quinagolide & Placebo in Preventing Ovarian Hyperstimulation Syndrome in Women Undergoing Controlled Ovarian Hyperstimulation.
Brief Summary: Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.


Options:
A: Arm Label: Cabergoline group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cabergoline | Arm Label: GnRH antagonist rescue & cabergoline group; Type: EXPERIMENTAL; Interventions: Drug: GnRH antagonist rescue & cabergoline | Intervention Type: DRUG; Name: Cabergoline; Assigned to Arm(s): Cabergoline group | Intervention Type: DRUG; Name: GnRH antagonist rescue & cabergoline; Assigned to Arm(s): GnRH antagonist rescue & cabergoline group
B: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Drug: Control | Arm Label: Cabergoline; Type: EXPERIMENTAL; Interventions: Drug: Cabergoline | Intervention Type: DRUG; Name: Cabergoline; Assigned to Arm(s): Cabergoline | Intervention Type: DRUG; Name: Control; Assigned to Arm(s): Control
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Norprolac | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Norprolac | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Norprolac | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Norprolac | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 4
D: Arm Label: Hemoes; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cabergoline; Type: EXPERIMENTAL; Interventions: Drug: Cabergoline and Hydroxyethyl Starch, Drug: Hydroxyethyl Starch | Intervention Type: DRUG; Name: Cabergoline and Hydroxyethyl Starch; Assigned to Arm(s): Cabergoline | Intervention Type: DRUG; Name: Hydroxyethyl Starch; Assigned to Arm(s): Cabergoline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Induction of Tolerance Through Early Introduction of Peanut in High-Risk Children (ITN032AD)
Brief Summary: This study will evaluate whether early exposure to peanuts promotes tolerance and provides protection from developing peanut allergy in children who are allergic to eggs or who have severe eczema.

This study has been continued into the ITN049AD (LEAP-On) Study (NCT01366846).


Options:
A: Arm Label: Observation only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Food intervention; Type: EXPERIMENTAL; Interventions: Other: Food intervention | Arm Label: Skin care; Type: EXPERIMENTAL; Interventions: Other: Skin care | Arm Label: Food intervention and skin care; Type: EXPERIMENTAL; Interventions: Other: Food intervention, Other: Skin care | Intervention Type: OTHER; Name: Food intervention; Assigned to Arm(s): Food intervention, Food intervention and skin care | Intervention Type: OTHER; Name: Skin care; Assigned to Arm(s): Food intervention and skin care, Skin care
B: Arm Label: Twice daily use treatment with EpiCeram; Type: ACTIVE_COMPARATOR; Interventions: Drug: EpiCeram | Arm Label: Standard skin care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: EpiCeram; Assigned to Arm(s): Twice daily use treatment with EpiCeram
C: Arm Label: Peanut Consumption Group; Type: EXPERIMENTAL; Interventions: Biological: Peanut Consumption Group | Arm Label: Peanut Avoidance Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Peanut Consumption Group; Assigned to Arm(s): Peanut Consumption Group
D: Arm Label: Balneum oil bath; Type: EXPERIMENTAL; Interventions: Other: Balneum oil bath | Arm Label: standard skin cleanser; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Balneum oil bath; Assigned to Arm(s): Balneum oil bath

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Induction of Tolerance Through Early Introduction of Peanut in High-Risk Children (ITN032AD)
Brief Summary: This study will evaluate whether early exposure to peanuts promotes tolerance and provides protection from developing peanut allergy in children who are allergic to eggs or who have severe eczema.

This study has been continued into the ITN049AD (LEAP-On) Study (NCT01366846).


Options:
A: Arm Label: Bathing within 24-48; Type: EXPERIMENTAL; Interventions: Procedure: Bathing | Arm Label: Bathing within 48-72; Type: EXPERIMENTAL; Interventions: Procedure: Bathing | Intervention Type: PROCEDURE; Name: Bathing; Assigned to Arm(s): Bathing within 24-48, Bathing within 48-72
B: Arm Label: Observation only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Food intervention; Type: EXPERIMENTAL; Interventions: Other: Food intervention | Arm Label: Skin care; Type: EXPERIMENTAL; Interventions: Other: Skin care | Arm Label: Food intervention and skin care; Type: EXPERIMENTAL; Interventions: Other: Food intervention, Other: Skin care | Intervention Type: OTHER; Name: Food intervention; Assigned to Arm(s): Food intervention, Food intervention and skin care | Intervention Type: OTHER; Name: Skin care; Assigned to Arm(s): Food intervention and skin care, Skin care
C: Arm Label: Peanut Consumption Group; Type: EXPERIMENTAL; Interventions: Biological: Peanut Consumption Group | Arm Label: Peanut Avoidance Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Peanut Consumption Group; Assigned to Arm(s): Peanut Consumption Group
D: Arm Label: Balneum oil bath; Type: EXPERIMENTAL; Interventions: Other: Balneum oil bath | Arm Label: standard skin cleanser; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Balneum oil bath; Assigned to Arm(s): Balneum oil bath

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Induction of Tolerance Through Early Introduction of Peanut in High-Risk Children (ITN032AD)
Brief Summary: This study will evaluate whether early exposure to peanuts promotes tolerance and provides protection from developing peanut allergy in children who are allergic to eggs or who have severe eczema.

This study has been continued into the ITN049AD (LEAP-On) Study (NCT01366846).


Options:
A: Arm Label: Peanut Consumption Group; Type: EXPERIMENTAL; Interventions: Biological: Peanut Consumption Group | Arm Label: Peanut Avoidance Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Peanut Consumption Group; Assigned to Arm(s): Peanut Consumption Group
B: Arm Label: Cereal L; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: electrolytic iron | Arm Label: Cereal M; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: ferrous fumarate | Intervention Type: DIETARY_SUPPLEMENT; Name: electrolytic iron; Assigned to Arm(s): Cereal L | Intervention Type: DIETARY_SUPPLEMENT; Name: ferrous fumarate; Assigned to Arm(s): Cereal M
C: Arm Label: Bright Futures; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Maternal focused intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Maternal focused intervention | Arm Label: Ounce of Prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ounce of Prevention | Intervention Type: BEHAVIORAL; Name: Maternal focused intervention; Assigned to Arm(s): Maternal focused intervention | Intervention Type: BEHAVIORAL; Name: Ounce of Prevention; Assigned to Arm(s): Ounce of Prevention
D: Arm Label: visit with grandmother; Type: EXPERIMENTAL; Interventions: Behavioral: counseling sessions | Arm Label: visit without grandmother; Type: EXPERIMENTAL; Interventions: Behavioral: counseling sessions | Arm Label: no visit with grandmother; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: no visit without grandmother; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: counseling sessions; Assigned to Arm(s): visit with grandmother, visit without grandmother

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Vaginally Administered Progesterone to Prevent Preterm Delivery in Twin Pregnancies - A Multicentre Randomized Trial
Brief Summary: The purpose of the study is to determine whether a daily dose of 200 mg progesterone administered vaginally from 20-23 to 34 weeks' gestation will reduce the rate of preterm delivery amongst twin pregnancies.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: 8% progesterone vaginal gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Vaginal Gel | Intervention Type: DRUG; Name: 8% progesterone vaginal gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Vaginal Gel; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Micronised progesterone (Utrogestan); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: 17 alpha-hydroxyprogesterone caproate (17P); Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Vaginally Administered Progesterone to Prevent Preterm Delivery in Twin Pregnancies - A Multicentre Randomized Trial
Brief Summary: The purpose of the study is to determine whether a daily dose of 200 mg progesterone administered vaginally from 20-23 to 34 weeks' gestation will reduce the rate of preterm delivery amongst twin pregnancies.


Options:
A: Intervention Type: DRUG; Name: Micronised progesterone (Utrogestan); Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: 17 alpha-hydroxyprogesterone caproate (17P); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: 8% progesterone vaginal gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Vaginal Gel | Intervention Type: DRUG; Name: 8% progesterone vaginal gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Vaginal Gel; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Vaginally Administered Progesterone to Prevent Preterm Delivery in Twin Pregnancies - A Multicentre Randomized Trial
Brief Summary: The purpose of the study is to determine whether a daily dose of 200 mg progesterone administered vaginally from 20-23 to 34 weeks' gestation will reduce the rate of preterm delivery amongst twin pregnancies.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: 8% progesterone vaginal gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Vaginal Gel | Intervention Type: DRUG; Name: 8% progesterone vaginal gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Vaginal Gel; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Micronised progesterone (Utrogestan); Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone (OHP17) | Intervention Type: DRUG; Name: Progesterone (OHP17); Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Pharmaco/Behavior Therapy in Adolescent Smokers
Brief Summary: In the current proposal, we intend to study the efficacy of bupropion SR with or without combined contingency management (CM) among adolescent cigarette smokers. The proposed study will test not only medication (bupropion SR), but also combination of medication and CM in potentially improving smoking cessation outcomes AND retention of adolescent smokers in the study.

Hypothesis to be tested: Bupropion SR treatment will increase abstinence from cigarette smoking (as measured by urine cotinine and continuous abstinence) in adolescent smokers as compared to treatment with placebo only.

Hypothesis to be tested: Adolescent smokers treated with combined bupropion SR + contingency management (CM) treatment will have increased retention and increased abstinence rates when compared to bupropion SR alone or CM + placebo treated groups (as measured by decreased drop-out of participants, urine cotinine and continuous abstinence).

Hypothesis to be tested: CM will increase the abstinence from cigarette smoking (as measured by urine cotinine and continuous abstinence) in adolescent smokers as compared to treatment with placebo only.


Options:
A: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
B: Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Placebo | Arm Label: Experimental: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Varenicline | Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling; Assigned to Arm(s): Experimental: Varenicline, Placebo Control | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Control | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Experimental: Varenicline
C: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
D: Arm Label: Bupropion SR + Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: Contingency Management | Arm Label: Placebo + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management, Other: Placebo | Arm Label: Bupropion SR + No Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo + No Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR + Contingency Management, Bupropion SR + No Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Bupropion SR + Contingency Management, Placebo + Contingency Management | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Contingency Management, Placebo + No Contingency Management

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long Term Study of 2 Isoniazid (INH) Prophylactic Regimens With Concomitant Cotrimoxazole (CTX) in HIV-infected Children - Impact on Morbidity, Mortality, Bacterial Resistance and Incidence of Tuberculosis
Brief Summary: The study involves use of isoniazid and cotrimoxazole as strategies for preventing infections in HIV-infected children and reducing mortality. Cotrimoxazole is well known to reduce mortality and infections in HIV-infected children and is currently the recommended standard of care. However, isoniazid has only been studied in HIV-infected adults (in whom it has been shown to substantially reduce the incidence of tuberculosis). In a randomised controlled study of isoniazid in HIV-infected children, the investigators found that INH reduced mortality and tuberculosis incidence in excess of 50%; the data safety monitoring board recommended termination of the placebo arm given the beneficial effects of INH. The investigators therefore aim to follow-up these children to compare the long term impact of two different INH and CTX preventive regimens (daily versus thrice weekly) on morbidity, mortality, adherence and incidence of adverse reactions. The investigators also aim to investigate the efficacy, safety and tolerability of INH compared with placebo for prevention of TB in children receiving HAART as the benefit in this group is unknown.


Options:
A: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: isoniazid , randomized, open label, Drug: rifampin, randomized, open label | Intervention Type: DRUG; Name: isoniazid , randomized, open label; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: rifampin, randomized, open label; Assigned to Arm(s): 1
B: Arm Label: Isoniazid preventive therapy; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid, Drug: Cotrimoxazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cotrimoxazole, Other: placebo | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): Isoniazid preventive therapy | Intervention Type: DRUG; Name: Cotrimoxazole; Assigned to Arm(s): Isoniazid preventive therapy, Placebo | Intervention Type: DRUG; Name: isoniazid; Assigned to Arm(s): Isoniazid preventive therapy | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: I ( isoniazid), II (isoniazid + rifampin ); Assigned to Arm(s): N/A
D: Arm Label: Daily Isoniazid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid (INH) daily for 9 months | Arm Label: Weekly Isoniazid / Rifapentine; Type: EXPERIMENTAL; Interventions: Drug: RPT + INH once weekly for 3 months given by DOT | Intervention Type: DRUG; Name: RPT + INH once weekly for 3 months given by DOT; Assigned to Arm(s): Weekly Isoniazid / Rifapentine | Intervention Type: DRUG; Name: Isoniazid (INH) daily for 9 months; Assigned to Arm(s): Daily Isoniazid

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preference and Vegetarian Diet in Weight Loss Treatment
Brief Summary: We propose to add a treatment preference component to a larger study testing standard behavioral treatment (SBT) for weight loss without specific food group restriction vs standard behavioral treatment with gradual elimination of meat, poultry, and fish \[a lacto-ovo-vegetarian (LOV) meal plan\]. Eligible respondents will be randomized to one of two conditions: Treatment Preference-Yes/No. Individuals in the Treatment Preference-Yes will be assigned to their choice (SBT or SBT+LOV), those in Treatment Preference-No will be randomized to either SBT or SBT+LOV without regard to their preference.


Options:
A: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention
B: Arm Label: Spouse-assisted intervention; Type: EXPERIMENTAL; Interventions: Behavioral: spouse-assisted intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: spouse-assisted intervention; Assigned to Arm(s): Spouse-assisted intervention
C: Arm Label: Standard Behavioral Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Behavioral Treatment | Arm Label: SBT+LOV Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Behavioral Treatment, Behavioral: SBT+LOV | Intervention Type: BEHAVIORAL; Name: Standard Behavioral Treatment; Assigned to Arm(s): SBT+LOV Group, Standard Behavioral Treatment | Intervention Type: BEHAVIORAL; Name: SBT+LOV; Assigned to Arm(s): SBT+LOV Group
D: Arm Label: Moderate lifestyle intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Moderate Lifestyle Intervention | Arm Label: Intensive lifestyle intervention; Type: EXPERIMENTAL; Interventions: Other: Intensive lifestyle intervention | Intervention Type: OTHER; Name: Moderate Lifestyle Intervention; Assigned to Arm(s): Moderate lifestyle intervention | Intervention Type: OTHER; Name: Intensive lifestyle intervention; Assigned to Arm(s): Intensive lifestyle intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.
Brief Summary: The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple myeloma (excluding breast and prostate cancer)


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid | Intervention Type: DRUG; Name: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid; Assigned to Arm(s): B
B: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: risedronate (including placebo) | Intervention Type: DRUG; Name: risedronate (including placebo); Assigned to Arm(s): A
C: Arm Label: zoledronic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zoledronic Acid | Arm Label: denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): denosumab | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): zoledronic acid
D: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab, Drug: Non-steroidal aromatase inhibitor therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Non-steroidal aromatase inhibitor therapy | Arm Label: SubStudy: Zoledronic Acid; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid | Arm Label: Substudy: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): Denosumab | Intervention Type: DRUG; Name: Non-steroidal aromatase inhibitor therapy; Assigned to Arm(s): Denosumab, Placebo | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): SubStudy: Zoledronic Acid | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Substudy: Standard of Care

Answer: C